Wockhardt has been granted a patent for nitrogen-containing bicyclic compounds (Formula I) for treating bacterial infections. The patent also covers pharmaceutical compositions containing these compounds. GlobalData’s report on Wockhardt gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Wockhardt, Anti-bacterial thiazole derivatives was a key innovation area identified from patents. Wockhardt's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11865108B2) discloses a compound of Formula (I) along with its stereoisomers and pharmaceutically acceptable salts. The compound includes various derivatives with different substituents, such as methyl, hydroxymethyl, aminomethyl, cyanomethyl, fluoromethyl, chloromethyl, mercaptomethyl, and various other functional groups. These derivatives can be used in pharmaceutical compositions for treating or preventing bacterial infections in subjects. The patent also covers the inclusion of antibacterial agents in the pharmaceutical compositions, particularly beta-lactam antibacterial agents like cefaclor, cefadroxil, cefalexin, cefdinir, cefixime, cefpirome, cefpodoxime, cefprozil, cefradine, ceftibuten, cefuroxime, loracarbef, and others, either alone or in combination with the disclosed compound.
The patent further extends to methods for treating or preventing bacterial infections in subjects by administering the disclosed compound or the pharmaceutical composition containing the compound and antibacterial agents. The inclusion of various antibacterial agents in the compositions provides a broad spectrum of treatment options for bacterial infections, enhancing the efficacy of the treatment. The patent's comprehensive coverage of different derivatives and their pharmaceutical applications underscores the potential for developing novel treatments for bacterial infections, addressing the growing need for effective antibacterial therapies in the medical field.
To know more about GlobalData’s detailed insights on Wockhardt, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
